Accordingly, several phase I/phase II clinical trials with CXCR1/CXCR2 antagonists or monoclonal anti-CXCL8 antibodies have been completed for treatment of COPD, however with conflicting results so far (vide infra). Here, CXCL8 is linked to chronic obstructive pulmonary disease.